7
748 Journal of Medicinal Chemistry, 2005, Vol. 48, No. 24
Hassani et al.
(
13) Ernster, L. DT Diaphorase. Methods Enzymol. 1967, 10, 309-
17.
14) Ernster, L. DT Diaphorase: A historical review. Chem. Scripta
987, 27A, 1-13.
15) Siegel, D.; Gibson, N. W.; Preusch, P. C.; Ross, D. Metabolism
of mitomycin C by DT-diaphorase: Role in mitomycin C-induced
DNA damage and cytotoxicity in human colon carcinoma cells.
Cancer Res. 1990, 50, 7483-7489.
16) Walton, M. I.; Smith, P. J.; Workman, P. The role of NAD(P)H:
quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive
bioactivation of the novel indoloquinone antitumor agent EO9.
Cancer Commun. 1991, 3, 199-206.
(34) Boger, D. L.; Yasuda, M.; Mitscher, L. A.; Drake, S. D.; Kitos,
P. A.; Thompson, S. C. Streptonigrin and lavendamycin partial
structures. Probes for the minimum, potent pharmacophore of
streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones.
J. Med. Chem. 1987, 30, 1918-1928.
(35) Hackethal, C. A.; Golbey, R. B.; Tan, C. T.; Karnofsky, D. A.;
Burchenal, J. H. Clinical observations on the effects of strep-
tonigrin in patients with neoplastic disease. Antibiot. Chemother.
1961, 11, 178-183.
(36) Fang, Y.; Linardic, C. M.; Richardson, D. A.; Cai, W.; Behforouz,
M.; Abraham, R. T. Characterization of the cytotoxic activities
of novel analogues of the antitumor agent, lavendamycin. Mol.
Cancer Ther. 2003, 2, 517-526.
(37) Behforouz, M.; Merriman, R. L. Lavendamycin analogues and
methods of making and using them. U.S. Patent 5525611, 1996.
(38) Behforouz, M.; Cai, W.; Stocksdale, M. G.; Lucas, J. S.; Jung, J.
Y.; Briere, D.; Wang, A.; Katen, K. S.; Behforouz, N. C. Novel
lavendamycin analogues as potent HIV-reverse transcriptase
inhibitors: Synthesis and evaluation of anti-reverse tran-
scriptase activity of amide and ester analogues of lavendamycin.
J. Med. Chem. 2003, 46, 5773-5780.
(39) Kende, A. S.; Ebetino, F. H. The regiospecific total synthesis of
lavendamycin methyl ester. Tetrahedron Lett. 1984, 25, 923-
926.
(40) Boger, D. L.; Duff, S. R.; Panek, J. S.; Yasuda, M. Total synthesis
of lavendamycim methyl ester. J. Org. Chem. 1985, 50, 5790-
5795.
(41) Behforouz, M.; Gu, Z.; Cai, W.; Horn, M. A.; Ahmadian, M. A
highly concise synthesis of lavendamycin methyl ester. J. Org.
Chem. 1993, 58, 7089-7091.
(42) Behforouz, M.; Haddad, J.; Cai, W.; Arnold, M. B.; Mohammadi,
F.; Sousa, A. C.; Horn, M. A. Highly efficient and practical
syntheses of lavendamycin methyl ester and related novel
quinolindiones. J. Org. Chem. 1996, 61, 6552-6555.
(43) Behforouz, M.; Zarrinmayeh, H.; Ogle, M. E.; Riehle, T. J.; Bell,
F. W. â-Carbolines derived from â-methyltryptophan and a
stereoselective synthesis of (2RS, 3SR)-â-methyltryptophan
methyl ester. J. Heterocycl. Chem. 1988, 25, 1627-1632.
(44) Behforouz, M.; Haddad, J.; Cai, W.; Gu, Z. Chemistry of
quinoline-5,8-diones. J. Org. Chem. 1998, 63, 343-346.
(45) Seradj, H.; Cai, W.; Erasga, N. O.; Chenault, D. V.; Knuckles,
K. A.; Ragains, J. R.; Behforouz, M. Total synthesis of novel
6-substituted lavendamycin antitumor agents. Org. Lett. 2004,
6, 473-476.
(46) Barret, R.; Daudon, M. Oxidation of phenols to quinones by bis-
(trifluoroacetoxy)iodobenzene. Tetrahedron Lett. 1990, 31, 4871-
4872.
(47) Tolstikov, V. V.; Holpne Kozlova, N. V.; Oreshkina, T. D.;
Osipova, T. V.; Preobrazhenskaya, M. N.; Sztaricskai, F.;
Balzarini, J.; De Clercq, E. Amides of antibiotic strepto-
nigrin and amino dicarboxylic acids or aminosugars. Synthesis
and biological evaluation. J. Antibiot. (Tokyo) 1992, 45, 1020-
1025.
(48) Cotterill, A. S.; Moody, C. J.; Mortimer, R. J.; Norton, C. L.;
O’Sullivan, N.; Stephens, M. A.; Stradiotto, N. R.; Swann, E.;
Stratford, I. J. Cyclopropamitosenes, novel bioreductive anti-
cancer agents. Synthesis, electrochemistry, and biological activ-
ity of 7-substituted cyclopropamitosenes and related indole-
quinones. J. Med. Chem. 1994, 37, 3834-3843.
(49) Beall, H. D.; Winski, S.; Swann, E.; Hudnott, A. R.; Cotterill, A.
S.; O’Sullivan, N.; Green, S. J.; Bien, R.; Siegel, D.; Ross, D.;
Moody, C. J. Indolequinone antitumor agents: Correlation
between quinone structure, rate of metabolism by recombinant
human NAD(P)H: quinone oxidoreductase, and in vitro cyto-
toxicity. J. Med. Chem. 1998, 41, 4755-4766.
(50) Swann, E.; Barraja, P.; Oberlander, A. M.; Gardipee, W. T.;
Hudnott, A. R.; Beall, H. D.; Moody, C. J. Indolequinone
antitumor agents: Correlation between quinone structure
and rate of metabolism by recombinant human NAD(P)H:
quinone oxidoreductase. Part 2. J. Med. Chem. 2001, 44, 3311-
3319.
(51) Fryatt, T.; Pettersson, H. I.; Gardipee, W. T.; Bray, K. C.; Green,
S. J.; Slawin, A. M.; Beall, H. D.; Moody, C. J. Novel quinoline-
quinone antitumor agents: Structure-metabolism studies with
NAD(P)H: quinone oxidoreductase (NQO1). Bioorg. Med. Chem.
2004, 12, 1667-1687.
3
(
1
(
(
(
17) Siegel, D.; Beall, H. D.; Senekowitsch, C.; Kasai, M.; Arai, H.;
Gibson, N. W.; Ross, D. Bioreductive activation of mitomycin C
by DT-diaphorase. Biochemistry 1992, 31, 7879-7885.
18) Naylor, M. A.; Swann, E.; Everett, S. A.; Jaffar, M.; Nolan, J.;
Robertson, N.; Lockyer, S. D.; Patel, K. B.; Dennis, M. F.;
Stratford, M. R.; Wardman, P.; Adams, G. E.; Moody, C. J.;
Stratford, I. J. Indolequinone antitumor agents: Reductive
activation and elimination from (5-methoxy-1-methyl-4,7-diox-
oindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity
in vitro. J. Med. Chem. 1998, 41, 2720-2731.
(
(
19) Siegel, D.; Gibson, N. W.; Preusch, P. C.; Ross, D. Metabolism
of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase
(
DT-diaphorase): Role in diaziquone-induced DNA damage and
cytotoxicity in human colon carcinoma cells. Cancer Res. 1990,
0, 7293-7300.
5
(
20) Schlager, J. J.; Powis, G. Cytosolic NAD(P)H:(quinone-acceptor)-
oxidoreductase in human normal and tumor tissue: Effects of
cigarette smoking and alcohol. Int. J. Cancer 1990, 45, 403-
409.
(
21) Malkinson, A. M.; Siegel, D.; Forrest, G. L.; Gazdar, A. F.; Oie,
H. K.; Chan, D. C.; Bunn, P. A.; Mabry, M.; Dykes, D. J.;
Harrison, S. D.; Ross, D. Elevated DT-diaphorase activity and
messenger RNA content in human non small cell lung carci-
noma: Relationship to the response of lung tumor xenografts
to mitomycin C. Cancer Res. 1992, 52, 4752-4757.
(
(
(
22) Cresteil, T.; Jaiswal, A. K. High levels of expression of the NAD-
(
P)H: quinone oxidoreductase (NQO1) gene in tumor cells
compared to normal cells of the same origin. Biochem. Pharma-
col. 1991, 42, 1021-1027.
23) Rampling, R.; Cruickshank, G.; Lewis, A. D.; Fitzsimmons, S.
A.; Workman, P. Direct measurement of pO2 distribution and
bioreductive enzymes in human malignant brain tumors. Int.
J. Radiat. Oncol. Biol. Phys. 1994, 29, 427-431.
24) Mikami, K.; Naito, M.; Ishiguro, T.; Yano, H.; Tomida, A.;
Yamada, T.; Tanaka, N.; Shirakusa, T.; Tsuruo, T. Immunologi-
cal quantitation of DT-diaphorase in carcinoma cell lines and
clinical colon cancers: Advanced tumors express greater levels
of DT-diaphorase. Jpn. J. Cancer Res. 1998, 89, 910-915.
25) Faig, M.; Bianchet, M. A.; Winski, S.; Hargreaves, R.; Moody,
C. J.; Hudnott, A. R.; Ross, D.; Amzel, L. M. Structure-based
development of anticancer drugs: Complexes of NAD(P)H:
quinone oxidoreductase 1 with chemotherapeutic quinones.
Structure 2001, 9, 659-667.
(
(
26) Winski, S. L.; Faig, M.; Bianchet, M. A.; Siegel, D.; Swann, E.;
Fung, K.; Duncan, M. W.; Moody, C. J.; Amzel, L. M.; Ross, D.
Characterization of a mechanism-based inhibitor of NAD(P)H:
quinone oxidoreductase 1 by biochemical, X-ray crystallographic,
and mass spectrometric approaches. Biochemistry 2001, 40,
15135-15142.
(
27) Zhou, Z.; Fisher, D.; Spidel, J.; Greenfield, J.; Patson, B.; Fazal,
A.; Wigal, C.; Moe, O. A.; Madura, J. D. Kinetic and docking
studies of the interaction of quinones with the quinone reductase
active site. Biochemistry 2003, 42, 1985-1994.
(
28) Cavelier, G.; Amzel, L. M. Mechanism of NAD(P)H: quinone
reductase: Ab initio studies of reduced flavin. Proteins: Struct.
Funct. Genet. 2001, 43, 420-432.
29) Doyle, T. W.; Balitz, D. M.; Grulich, R. E.; Nettleton, D. E.;
Gould, S. J.; Tann, C.; Moews, A. E. Structure determination of
lavendamycin, a new antitumor antibiotic from Streptomyces
lavendulae. Tetrahedron Lett. 1981, 22, 4595-4598.
(
(
(
(
(
30) Balitz, D. M.; Bush, J. A.; Bradner, W. T.; Doyle, T. W.; O’Herron,
F. A.; Nettleton, D. E. Isolation of lavendamycin, a new antibiotic
from Streptomyces lavendulae. J. Antibiot. (Tokyo) 1982, 35,
2
59-265.
31) Erickson, W. R.; Gould, S. J. Streptonigrin biosynthesis. 7.
Incorporation of oxygen from 18
Evidence for an oxida-
tive â-carboline cleavage. J. Am. Chem. Soc. 1985, 107, 5831-
832.
(52) Phillips, R. M.; Naylor, M. A.; Jaffar, M.; Doughty, S. W.; Everett,
S. A.; Breen, A. G.; Choudry, G. A.; Stratford, I. J. Bioreductive
activation of a series of indolequinones by human DT-diapho-
rase: Structure-activity relationships. J. Med. Chem. 1999, 42,
4071-4080.
(53) Winski, S. L.; Hargreaves, R. H.; Butler, J.; Ross, D. A new
screening system for NAD(P)H:quinone oxidoreductase (NQO1)-
directed antitumor quinones: Identification of a new aziridinyl-
hfbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Clin. Cancer Res. 1998, 4, 3083-3088.
2
O :
5
32) Erickson, W. R.; Gould, S. J. Streptonigrin Biosynthesis. 8.
Evidence for the involvement of a new Shikimate pathway
product and a new route to quinolines. J. Am. Chem. Soc. 1987,
109, 620-621.
33) Rao, K. V.; Biemann, K.; Woodward, R. B. The structure of
streptonigrin. J. Am. Chem. Soc. 1963, 85, 2532-2533.